DECLARE-TIMI 58 HF Risk Reduction Score Calculator

Clinical calculation support · Verify results before clinical use

Patient profile

Complete all fields using the stated units.

—Score
Reset

Clinical context

DECLARE–TIMI 58 evaluated dapagliflozin versus placebo in people with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease. The trial reported a reduction in the composite of cardiovascular death or hospitalization for heart failure, driven by fewer hospitalizations for heart failure.

This page preserves the original code's input variables, point assignments, and score cutoffs for transparency, but labels the result as a simplified educational score. It does not calculate a validated absolute event probability, number needed to treat, or individual treatment benefit.

Scoring rules in the supplied source code

VariableOriginal rulePoints
Age≥75 years / 65–74 years+2 / +1
History of HFYes+3
Established ASCVDYes+1
eGFR<60 / 60–89 mL/min/1.73 m²+2 / +1
AlbuminuriaUACR ≥30 mg/g+2
HbA1c≥8%+1
SexMale+0.5

Original code's categories: score ≥7, high; score ≥4 and <7, moderate; score <4, low. These are code-defined categories, not validated clinical risk strata.

References

Wiviott SD, Raz I, Bonaca MP, et al.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347–357. DOI: 10.1056/NEJMoa1812389.
DECLARE–TIMI 58 Trial — TIMI Study GroupOfficial trial overview and main results. Open trial resource.
Clinical disclaimer: This calculator is intended for educational use and must not be used as a stand-alone diagnostic, prognostic, or prescribing tool. The simplified point system has not been validated as a prediction model. Clinical decisions should be based on the patient's complete clinical profile, current evidence, and relevant guidelines.